VolitionRX Aktie News

VolitionRx Limited (NYSE:VNRX ) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Cameron Reynolds - President, CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Louise Batchelor - Chief Marketing & Communications Officer Conference Call Participants Bruce Jackson - Benchmark Company Tim Moore - EF Hutton Ilya Zubkov - Freedom Broker Steven Ralston - Zack...

Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

HENDERSON, Nev. , April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.

VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.